Lactam-based HDAC inhibitors for anticancer chemotherapy: Restoration of RUNX3 by posttranslational modification and epigenetic control

Misun Cho, Eunhyun Choi, Jae Hyun Kim, Hwan Kim, Hwan Mook Kim, Jang Ik Lee, Ki Chul Hwang, Hyun Jung Kim, Gyoonhee Han

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Expression and stability of the tumor suppressor runt-related transcription factora 3 (RUNX3) are regulated by histone deacetylase (HDAC). HDAC inhibition alters epigenetic and posttranslational stability of RUNX3, leading to tumor suppression. However, HDAC inhibitors can nonselectively alter global gene expression through chromatin remodeling. Thus, lactam-based HDAC inhibitors were screened to identify potent protein stabilizers that maintain RUNX3 stability by acetylation. RUNX activity and HDAC inhibition were determined for 111 lactam-based analogues through a cell-based RUNX activation and HDAC inhibition assay. 3-[1-(4-Bromobenzyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-N- hydroxypropanamide (11-8) significantly increased RUNX3 acetylation and stability with relatively low RUNX3 mRNA expression and HDAC inhibitory activity. This compound showed significant antitumor effects, which were stronger than SAHA, in an MKN28 xenograft model. Thus, we propose a novel strategy, in which HDAC inhibitors serve as antitumor chemotherapeutic agents that selectively target epigenetic regulation and protein stability of RUNX3.

Original languageEnglish
Pages (from-to)649-656
Number of pages8
JournalChemMedChem
Volume9
Issue number3
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Lactams
Histone Deacetylase Inhibitors
Histone Deacetylases
Chemotherapy
Post Translational Protein Processing
Epigenomics
Restoration
Drug Therapy
Acetylation
Tumors
Chromatin Assembly and Disassembly
Protein Stability
Transcription
Heterografts
Gene expression
Antineoplastic Agents
Chromatin
Assays
Neoplasms
Proteins

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

Cho, Misun ; Choi, Eunhyun ; Kim, Jae Hyun ; Kim, Hwan ; Kim, Hwan Mook ; Lee, Jang Ik ; Hwang, Ki Chul ; Kim, Hyun Jung ; Han, Gyoonhee. / Lactam-based HDAC inhibitors for anticancer chemotherapy : Restoration of RUNX3 by posttranslational modification and epigenetic control. In: ChemMedChem. 2014 ; Vol. 9, No. 3. pp. 649-656.
@article{bd65d65623f74c3ab013b8fc9d310bb3,
title = "Lactam-based HDAC inhibitors for anticancer chemotherapy: Restoration of RUNX3 by posttranslational modification and epigenetic control",
abstract = "Expression and stability of the tumor suppressor runt-related transcription factora 3 (RUNX3) are regulated by histone deacetylase (HDAC). HDAC inhibition alters epigenetic and posttranslational stability of RUNX3, leading to tumor suppression. However, HDAC inhibitors can nonselectively alter global gene expression through chromatin remodeling. Thus, lactam-based HDAC inhibitors were screened to identify potent protein stabilizers that maintain RUNX3 stability by acetylation. RUNX activity and HDAC inhibition were determined for 111 lactam-based analogues through a cell-based RUNX activation and HDAC inhibition assay. 3-[1-(4-Bromobenzyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-N- hydroxypropanamide (11-8) significantly increased RUNX3 acetylation and stability with relatively low RUNX3 mRNA expression and HDAC inhibitory activity. This compound showed significant antitumor effects, which were stronger than SAHA, in an MKN28 xenograft model. Thus, we propose a novel strategy, in which HDAC inhibitors serve as antitumor chemotherapeutic agents that selectively target epigenetic regulation and protein stability of RUNX3.",
author = "Misun Cho and Eunhyun Choi and Kim, {Jae Hyun} and Hwan Kim and Kim, {Hwan Mook} and Lee, {Jang Ik} and Hwang, {Ki Chul} and Kim, {Hyun Jung} and Gyoonhee Han",
year = "2014",
month = "3",
day = "1",
doi = "10.1002/cmdc.201300393",
language = "English",
volume = "9",
pages = "649--656",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

Lactam-based HDAC inhibitors for anticancer chemotherapy : Restoration of RUNX3 by posttranslational modification and epigenetic control. / Cho, Misun; Choi, Eunhyun; Kim, Jae Hyun; Kim, Hwan; Kim, Hwan Mook; Lee, Jang Ik; Hwang, Ki Chul; Kim, Hyun Jung; Han, Gyoonhee.

In: ChemMedChem, Vol. 9, No. 3, 01.03.2014, p. 649-656.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lactam-based HDAC inhibitors for anticancer chemotherapy

T2 - Restoration of RUNX3 by posttranslational modification and epigenetic control

AU - Cho, Misun

AU - Choi, Eunhyun

AU - Kim, Jae Hyun

AU - Kim, Hwan

AU - Kim, Hwan Mook

AU - Lee, Jang Ik

AU - Hwang, Ki Chul

AU - Kim, Hyun Jung

AU - Han, Gyoonhee

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Expression and stability of the tumor suppressor runt-related transcription factora 3 (RUNX3) are regulated by histone deacetylase (HDAC). HDAC inhibition alters epigenetic and posttranslational stability of RUNX3, leading to tumor suppression. However, HDAC inhibitors can nonselectively alter global gene expression through chromatin remodeling. Thus, lactam-based HDAC inhibitors were screened to identify potent protein stabilizers that maintain RUNX3 stability by acetylation. RUNX activity and HDAC inhibition were determined for 111 lactam-based analogues through a cell-based RUNX activation and HDAC inhibition assay. 3-[1-(4-Bromobenzyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-N- hydroxypropanamide (11-8) significantly increased RUNX3 acetylation and stability with relatively low RUNX3 mRNA expression and HDAC inhibitory activity. This compound showed significant antitumor effects, which were stronger than SAHA, in an MKN28 xenograft model. Thus, we propose a novel strategy, in which HDAC inhibitors serve as antitumor chemotherapeutic agents that selectively target epigenetic regulation and protein stability of RUNX3.

AB - Expression and stability of the tumor suppressor runt-related transcription factora 3 (RUNX3) are regulated by histone deacetylase (HDAC). HDAC inhibition alters epigenetic and posttranslational stability of RUNX3, leading to tumor suppression. However, HDAC inhibitors can nonselectively alter global gene expression through chromatin remodeling. Thus, lactam-based HDAC inhibitors were screened to identify potent protein stabilizers that maintain RUNX3 stability by acetylation. RUNX activity and HDAC inhibition were determined for 111 lactam-based analogues through a cell-based RUNX activation and HDAC inhibition assay. 3-[1-(4-Bromobenzyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-N- hydroxypropanamide (11-8) significantly increased RUNX3 acetylation and stability with relatively low RUNX3 mRNA expression and HDAC inhibitory activity. This compound showed significant antitumor effects, which were stronger than SAHA, in an MKN28 xenograft model. Thus, we propose a novel strategy, in which HDAC inhibitors serve as antitumor chemotherapeutic agents that selectively target epigenetic regulation and protein stability of RUNX3.

UR - http://www.scopus.com/inward/record.url?scp=84896719529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896719529&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201300393

DO - 10.1002/cmdc.201300393

M3 - Article

C2 - 24376239

AN - SCOPUS:84896719529

VL - 9

SP - 649

EP - 656

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 3

ER -